NBY - NovaBay Pharmaceuticals Inc Stock Price, Fair Value and News

$1.05+0.03 (+2.94%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NBY Price Action

Last 7 days

2.9%

Last 30 days

-3.7%

Last 90 days

-75.1%

Trailing 12 Months

84.2%

NBY RSI Chart

NBY Valuation

Market Cap

132.3M

Price/Earnings (Trailing)

40.8

Price/Sales (Trailing)

17.25

EV/EBITDA

-9.27

Price/Free Cashflow

-18.56

NBY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NBY Fundamentals

NBY Revenue

Revenue (TTM)

7.7M

Rev. Growth (Yr)

-78.66%

Rev. Growth (Qtr)

-77.44%

NBY Earnings

Earnings (TTM)

3.2M

Earnings Growth (Yr)

-6.68%

Earnings Growth (Qtr)

32.73%

NBY Profitability

EBT Margin

-179.09%

Return on Equity

292.43%

Return on Assets

93%

Free Cashflow Yield

-5.39%

NBY Investor Care

Shares Dilution (1Y)

2479.18%

Diluted EPS (TTM)

-1.05

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	0	0	7.7M	0
2024	10.7M	9.6M	9.6M	9.8M
2023	13.5M	13.3M	12.0M	10.5M
2022	11.3M	12.8M	14.3M	14.4M
2021	9.8M	8.0M	8.1M	9.8M
2020	7.0M	9.2M	9.8M	9.9M
2019	11.1M	10.0M	8.5M	6.6M
2018	17.5M	16.1M	15.2M	12.5M
2017	13.9M	15.3M	16.0M	18.2M
2016	5.6M	7.2M	9.5M	11.9M
2015	1.4M	2.2M	3.3M	4.4M
2014	2.7M	2.0M	1.1M	1.0M
2013	6.6M	6.5M	4.0M	3.5M
2012	9.8M	6.2M	7.1M	6.9M
2011	10.2M	12.1M	12.8M	11.0M
2010	0	13.7M	11.7M	9.8M

Get all data in R, Python etc through our Historical Stock Data APIs

About NovaBay Pharmaceuticals Inc

NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.

CEO	Mr. Justin M. Hall Esq.
WEBSITE	https://novabay.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	29

NovaBay Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for NovaBay Pharmaceuticals Inc? What does NBY stand for in stocks?

NBY is the stock ticker symbol of NovaBay Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NovaBay Pharmaceuticals Inc (NBY)?

As of Wed Dec 03 2025, market cap of NovaBay Pharmaceuticals Inc is 132.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NBY stock?

You can check NBY's fair value in chart for subscribers.

Is NovaBay Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether NBY is over valued or under valued. Whether NovaBay Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact NovaBay Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NBY.

What is NovaBay Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, NBY's PE ratio (Price to Earnings) is 40.8 and Price to Sales (PS) ratio is 17.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NBY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on NovaBay Pharmaceuticals Inc's stock?

In the past 10 years, NovaBay Pharmaceuticals Inc has provided -0.565 (multiply by 100 for percentage) rate of return.